Study on Adapt NK Cell Therapy for High-Risk Myeloid Diseases as a Bridge to Stem Cell Transplant

Inclusion Criteria

• Adults aged 18 to 74 with a good performance status (Karnofsky score of 70% or higher).
• Adults aged 75 and older with a good performance status, low health risk score, and not considered frail.
• Specific genetic markers (HLA type C1/C1 or C2/C2).
• Good liver, kidney, lung, and heart function.
• Able to stop taking steroids and other immune-suppressing drugs for at least 28 days before receiving AdaptNK cells.
• Enough time must have passed since the last cancer treatment, such as:
  • 2 weeks after chemotherapy
  • 3 half-lives after targeted therapy
  • 1 week after radiotherapy
  • 6 weeks after donor lymphocyte infusions
  • 1 week after growth factors
  • 2 weeks after biological therapy
  • 4 weeks after immune cell therapy
• No active leukemia in the central nervous system, confirmed by two negative spinal fluid tests.
• White blood cell count must be below 25,000 before infusion.
• All previous treatment side effects should be mild or resolved.
• Agree to use effective birth control during the study and for 4 months after treatment.
• Willing to provide written consent to participate.

Exclusion Criteria

• Certain genetic myeloid diseases, except specific types like DDX41, TP53, or RUNX1.
• Acute promyelocytic leukemia (APL).
• Recent heart attack within the last 6 months.
• Pregnant or breastfeeding women.
• Active leukemia in the central nervous system.
• New or worsening lung issues.
• Active autoimmune diseases needing treatment.
• Severe asthma requiring ongoing medication.
• Positive for HIV or hepatitis B/C.
• Active infections needing treatment.
• Recent use of experimental drugs within 14 days before starting the study.
• Other cancers needing treatment within the last year, unless stable on hormonal therapy for breast or prostate cancer.
• Patients with treated skin cancer or early-stage prostate cancer are eligible.